Welcome to our dedicated page for Sinovac Biotech news (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech stock.
Sinovac Biotech Ltd. (NASDAQ: SVA) is a China-based global biopharmaceutical company focused on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The SVA news page on Stock Titan aggregates company press releases, regulatory updates, and third-party coverage so readers can follow developments affecting this vaccine manufacturer.
News about Sinovac frequently centers on its vaccine portfolio and public health role, including products such as CoronaVac® for COVID‑19, Healive® for hepatitis A, Inlive® for EV71-related Hand-Foot-Mouth disease (HFMD), and vaccines for varicella, influenza, poliomyelitis, and pneumococcal disease. Articles also highlight WHO prequalification of several Sinovac vaccines and the company’s history of developing vaccines during outbreaks of SARS, H5N1, H1N1, and COVID‑19.
Investors and observers can also use this page to track corporate governance, legal, and listing-related news. Recent company communications describe litigation in Antigua over PIPE shares and shareholder voting, competing claims regarding board composition, and court orders governing Sinovac’s board and corporate actions. Updates on proxy contests, special shareholder meetings, and dividend decisions are commonly reported through company press releases and furnished to the SEC on Form 6‑K.
Another key news theme is financial reporting and auditor engagement. Sinovac has issued announcements about the resignation and appointment of independent auditors, the engagement of UHY LLP and later Zhonghua Certified Public Accountants LLP, and its efforts to complete multi-year audits and file outstanding Form 20‑Fs and Form 6‑Ks. Related Nasdaq notices regarding late filings and a delisting determination letter are also disclosed in news items.
By reviewing the SVA news feed, readers can monitor Sinovac’s vaccine-related milestones, regulatory and legal developments, dividend actions, and progress toward meeting SEC and Nasdaq requirements. This page can be revisited regularly for the latest company-issued statements and market-relevant updates.
Sinovac Biotech Ltd. (NASDAQ: SVA) has received a notification from Nasdaq on May 16, 2025, regarding its non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the late filing of its 2024 Annual Report. The company has until July 15, 2025 to submit a compliance plan to Nasdaq. If accepted, Sinovac may receive an extension until November 11, 2025, to regain compliance.
The delay stems from the resignation of Grant Thornton Zhitong Certified Public Accountants LLP as the company's independent auditor on April 15, 2025. Sinovac's audit committee is currently evaluating potential new accounting firms to complete the 2024 Annual Report filing.
Sinovac Biotech (NASDAQ: SVA), a leading Chinese biopharmaceutical company, has announced key dates for its previously declared special cash dividend. The company will distribute US$55.00 per common share to shareholders.
Key details of the dividend distribution:
- Record Date: May 23, 2025 (close of business, ET)
- Payment Date: Expected around July 9, 2025
- Dividend Amount: $55.00 per common share
- Payment Method: Cash
This special dividend announcement follows the company's initial declaration made on April 1, 2025. The payment will be made to valid holders of Sinovac's common shares as recorded by the specified date.
Sinovac Biotech board of directors issued a public letter to shareholders addressing hostile actions by Vivo Capital. The key dispute centers around a US$55.00 per share special cash dividend announcement and board legitimacy following a 2018 Annual General Meeting.
The situation stems from a January 2025 Privy Council ruling that validated the 2018 board election results, declaring the former Vivo-controlled board as "imposters." The new board aims to distribute dividends to shareholders who received nothing for seven years, while Vivo Capital, through a subsidiary, already received over US$800 million in dividends from 2021-2024.
Key developments include the resignation of auditor Grant Thornton, NASDAQ trading halt since 2019, and disputes over a PIPE investment. The board plans to set aside additional US$11.00 per share pending PIPE shares cancellation. The company is working toward resuming NASDAQ trading and implementing the dividend plan despite legal challenges from Vivo Capital.
FAQ
What is the market cap of Sinovac Biotech (SVA)?
